Archive
-
2022/03/23Press Release: Furmonertinib Being a First-line Drug to Treat Patients Suffering from Advanced NSCLC, with Progression-free Survival (PFS) of 20.8 Months
-
2022/01/04A New Year Begins with Furmonertinib Added to China’s National Medical Insurance Catalog
-
2022/01/012021 Allist Pharmaceutical Milestones: Keep Innovating, Keep Moving Forward
-
2021/12/31New Release! Furmonertinib Included in the "Guidelines for Clinical Application of Novel Antitumor Drugs (2021 Edition)"
-
2021/10/31Good news in October: Furmonertinib has quickly covered 10 cities.
-
2021/10/29Accelerated Breakthrough: Allist’s Q3 financial report. Performance overview:
-
2021/09/22Allist Chief Chemistry Officer Dr. Luo Huibing: “Precision R&D” with Artistic Elegance
-
2021/09/02Dongguan Citizen Insurance Upgraded: Care-free Furmonertinib
-
2021/09/01Furmonertinib Entered Wuxi: Inclusive Commercial Insurance List Upgraded
-
2021/09/01Lecheng, Boao rolls out global special drug insurance 2021 where Furmonertinib incorporated!